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Abstract Exendin-4 is a GLP-1 analog used for the treatment
of type 2 diabetes mellitus in its synthetic form. As women
with diabetes have higher breast cancer incidence and mortal-
ity, we examined the effect of the incretin drug exendin-4 on
breast cancer cells. The aim of the study is to investigate
anticancer mechanism of exendin-4 in MCF-7 breast cancer
cells. Cytotoxic effects of exendin-4 were determined by XTT
assay. IC50 dose inMCF-7 cells were detected as 5 μMat 48th
hour. Gene messenger RNA (mRNA) expressions were eval-
uated by real-time PCR. According to results, caspase-9, Akt,
andMMP2 expression was reduced in dose group cells, com-
pared with the control group cells. p53, caspase-3, caspase-8,
caspase-10, BID, DR4, DR5, FADD, TRADD, PARP, PTEN,
PUMA, NOXA, APAF, TIMP1, and TIMP2 expression was
increased in dose group cells, compared with the control
group cells. Effects of exendin-4 on cell invasion, colony for-
mation, and cell migration were detected by Matrigel cham-
ber, colony formation assay, and wound-healing assay, respec-
tively. To conclude, it is thought that exendin-4 demonstrates
anticarcinogenesis activity by effecting apoptosis, invasion,
migration, and colony formation in MCF-7 cells. Exendin-4
may be a therapeutic agent for treatment of breast cancer as
single or in combination with other agents. More detailed
researches are required to define the pathways of GLP-1 effect
on breast cancer cells because of the molecular biology of
breast cancer that involves a complex network of intercon-
nected signaling pathways that have role in cell growth, sur-
vival, and cell invasion.
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Abbreviations
DM Diabetes mellitus
GLP-
1
Glucagon-like peptide-1
GPCR G protein-coupled receptor
IGF-1 Insulin-like growth factor 1
XTT 2,3-Bis-(2-Metoksi-4-nitro-5-sülfofenil)-2H-tetra-
zolium-5-carboxanilide
Introduction
In addition to the known complications of diabetes, there is
emerging evidence that diabetes mellitus (DM) patients may
face a higher risk of developing cancer [1] and a higher cancer
mortality [2], particularly for breast cancer [2, 3]. Various
factors may be related to obesity, diabetes, and breast cancer
risk, contain activation of insulin and insulin-like growth fac-
tor 1 (IGF-1) pathways, altered regulation of endogenous sex
hormones, and altered levels of adipocytokines [4–9].
Glucagon-like peptide (GLP)-1 is situated in the incretin
system and secreted from intestinal L cells. It demonstrates its
actions via the GLP-1 receptor (GLP-1R)—a G protein-
coupled receptor (GPCR) expressed on pancreatic β cells
and other tissues, including the brain, heart, and smooth mus-
cle [9, 10]. Different activities of GLP-1 have been defined to
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date. For instance, GLP-1 stimulates insulin secretion from β
cells, modulates their proliferation and differentiation, and in-
hibits their apoptosis [9, 11]. Furthermore, GLP-1 is a strong
inhibitor of gastric emptying and a promoter of satiety;
sustained activation of the GLP-1R is related to weight loss
[12]. Some researches suggest that GLP-1 may increase insu-
lin sensitivity in peripheral tissues [13, 14]. Exendin-4 is a
more stable GLP-1 analog [15] currently used for the treat-
ment of type 2 diabetes mellitus in its synthetic form exenatide
[16].
GLP-1-based therapy on breast cancer may have signifi-
cant clinical implications because of the fact that type 2 DM,
obesity, and breast cancer commonly appear together [2, 16].
Recently, several studies have been reported on the effects of
GLP-1 and exendin-4 on cancer cells. In these studies, an
inhibitory effect of exendin-4 on cell growth in colon CT26
[17] and in MCF-7 and MDA-MB-231 breast [9] cancer cells
has been reported. We aimed to evaluate the effects of
exenatide on breast cancer cell proliferation and viability; be-
sides, this evaluates the effects on cell migration, cell invasion,
and colony formation capacity in this study.
Material and methods
Cell culture
MCF-7 human breast cancer cell (obtained fromATCC, USA)
line was used in this study. MCF-7 cells were grown in
DMEM medium supplemented with 2 mM L-glutamine, pen-
icillin (20 units/ml), streptomycin (20 μg/ml), and 10 % (v/v)
heat-inactivated fetal calf serum at 37 °C in a saturated humid-
ity atmosphere containing 95% air and 5%CO2.MCF-7 cells
were treated with 0.25, 0.5, 1, 1.5, 2, 3, 5, 7.5, and 10 μM
exendin-4 by solving in medium during 72 h, considering a
time- and dose-dependent manner.
Cytotoxicity assay
Cytotoxicity assays and determination of IC50 dose of
exendin-4 in MCF-7 cells were performed by using trypan
blue dye exclusion test and XTT assay as indicated in the
manufacturers’ instruction.
XTT assay
Cells were seeded in 96-well tissue culture plates and incubat-
ed for 24 h without reagent. After addition of reagents, cells
were incubated for 24, 48, and 72 h and cell viability was
assessed by using XTT (2,3-bis-(2-Metoksi-4-nitro-5-sülfofe-
nil)-2H-tetrazolium-5-carboxanilide) mixture as recommend-
ed by the supplier. Formazan formation was quantified spec-
trophotometrically at 450 nM (reference wavelength 630 nM)
using a microplate reader. Viability was calculated using the
background-corrected absorbance as follows:
Viability %ð Þ ¼ Aof experimentwell=Aof controlwell 100
RNA isolation and real-time PCR
Total RNAwas isolated from the cells exposed to IC50 doses
of exendin-4 with TRIzol Reagent (İnvitrogen, USA) accord-
ing to the manufacturer’s instructions. Complementary DNA
(cDNA) synthesis was performed by using Transcriptor First-
Strand cDNA Synthesis Kit (Roche, Germany). p53, caspase-
3, caspase-9, caspase-8, caspase-10, Bcl-2, BCL-XL, BID,
DR4, DR5, FADD, TRADD, PARP, APAF, Bax, Akt, PTEN,
PUMA, NOXA,MMP2,MMP9, TIMP1, TIMP2 gene expres-
sion was performed on real-time RT-PCR according to the
SYBR Green qPCR Master Mix (Thermo Scientific, USA)
protocol. RT-PCR assay was performed using gene-specific
primers. The expression results were proportioned to the
GAPDH gene (housekeeping gene) expressions to calculate
relative expression rations. Primer sequences were given in
Table 1.
Cell migration and invasion assay
Invasion activities of control and dose group cells were deter-
mined according to the BioCoat Matrigel Invasion Chamber
guide (BD Biosciences). The cells with serum-free DMEM
were seeded at a density of 2×105 cells/well onto the upper
chambers of Matrigel-coated filter inserts, and serum-
containing DMEM (500μl) was added to the lower chambers.
Then, the cells were incubated at 37 °C for 24 h. After of
incubation, filter inserts were removed from the wells. The
cells on the upper surface of the filter were wiped with a cotton
swab. Filters were fixed with methanol for 10 min and stained
with crystal violet. The cells that invaded the lower surface of
the filter were counted under a light microscope. Each exper-
iment was repeated three times. Percentage of invasion was
calculated using control and Matrigel membrane cell count as
follows:
Invasion %ð Þ ¼ The number of cells in matrigel matrix basement membrane
The number of cells in control membrane
 100
Colony assay
For colony formation analysis, the cells were digested with
trypsin, counted using trypan blue dye exclusion test, and
seeded in six-well plates at a density of 103 cells per well.
The medium was changed every 3 days for 15 days until
visible colonies formed. Colonies were fixed methanol for
10 min and stained with crystal violet.
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Wound-healing assay
The control and dose group cells were plated at 106 cells per
well of 60×15 mm style cell culture dishes and grown over-
night at 37 °C with 5 % CO2. The 80 % confluent control
group and dose group cells were treated with 5 μM exendin-
4 after a straight line scratch was made on a confluent mono-
layer of cells using a sterile 200-μl plastic pipette tip. To re-
move debris and smooth the edge of the scratch, the cells were
washed with 2 ml serum-free DMEM. Images of the MCF-7
cell proliferation were taken at 0 16, 24, and 48 h after the
scratch. The scratch assay was performed in triplicate.
Statistical analysis
The analysis of the findings has been made with the ΔΔCT
method and quantitated with a computer program. The com-
parison of the groups has been performed with BVolcano.Plot^
analysis, from BRT2.ProfilesTMPCR Array Data Analysis^,
which is assessed statistically using the BStudent t test.^More-
over, parametric and non-parametric analysis of doses and
controls has been evaluated with the SPSS 17.0 statistical
analysis program (p<0.05 is significant statistically).
Results
Cytotoxic activity
XTT assay
MCF-7 cell death upon treatment with exendin-4 was assessed
by the XTT (2,3-bis-(2-Metoksi-4-nitro-5-sülfofenil)-2H-tet-
razolium-5-carboxanilide) assay. Time- and dose-dependent
decrease patterns were found in the viability of MCF-7 cells.
For this purpose, the expression changes of genes are evalu-
ated by treating different concentration of exendin-4 at the
24th, 48th, and 72nd hour in MCF-7 cells. In our study, IC50
doses (inhibitory concentration where 50% of the cells die) in
the MCF-7 cells were detected as 5 μM at 48th hour by XTT
assay (Fig. 1).
Real-time PCR
After total RNA was isolated from control and exendin-4-
treated cells, the cDNA synthesis have been performed by
using Transcriptor First-Strand cDNA Synthesis Kit (Roche
Diagnostics, Germany). The expression analysis of p53,
caspase-3, caspase-9, caspase-8, caspase-10, Bcl-2, BCL-
XL, BID, DR4, DR5, FADD, TRADD, PARP, APAF, Bax,
Akt, PTEN, PUMA, NOXA, MMP2, MMP9, TIMP1, TIMP2
was studied on real-time RT-PCR according to the SYBR
Green qPCR Master Mix (Thermo Scientific) protocol. Real-
Table 1 Primer sequences of the genes used in this study
Name Primer sequence
APAF F: ATGAGCCCACTCAACAGCAA
R: GTCCTTACACTGGAAGAAGAGAC
BAX F: AGAGGATGATTGCCGCCGT
R: CAACCACCCTGGTCTTGGATC
Caspase-3 F: GCAGCAAACCTCAGGGAAAC
R: TGTCGGCATACTGTTTCAGCA
BCL-2 F: TTGGCCCCCGTTGCTT
R: CGGTTATCGTACCCCGTTCTC
GAPDH F: TTCTATAAATTGAGCCCGCAGCC
R: CCGTTGACTCCGACCTTCAC
Caspase-9 F: GGCTGTCTACGGCACAGATGGA
R: CTGGCTCGGGGTTACTGCCAG
p21 F: TGGAGACTCTCAGGGTCGAAA
R: GGCGTTGGAGTGGTAGAAATC
p53 F: ATCTACAAGCAGTCACAGCACAT
R: GTGGTACAGTCAGAGCCAACC
PTEN F: CCCAGACATGACAGCCATC
R: TCTGCAGGAAATCCCATAGC
PARP F: ACACCCCTTGCACGTACTTC
R: GATGGGTTCTCTGAGCTTCG
PUMA F: GACCTCAACGCACAGTACGAG
R: AGGAGTCCCATGATGAGATTGT
NOXA F: ACCAAGCCGGATTTGCGATT
R: ACTTGCACTTGTTCCTCGTGG
BID F: CCTACCCTAGAGACATGGAGAAG
R: TTTCTGGCTAAGCTCCTCACG
AKT F: CAACTTCTCTGTGGCGCAGTG
R: GACAGGTGGAAGAACAGCTCG
BCL-XL F: GGTCGCATTGTGGCCTTTTTC
R: TGCTGCATTGTTCCCATAGAG
DR4 (TNFRSF10A) F: GCGGGGAGGATTGAACCAC
R: CGACGACAAACTTGAAGGTCTT
DR5 (TNFRSF10B) F: ACAGTTGCAGCCGTAGTCTTG
R: CCAGGTCGTTGTGAGCTTCT
FADD F: GCTGGCTCGTCAGCTCAAA
R: ACTGTTGCGTTCTCCTTCTCT
TRADD F: GCTGTTTGAGTTGCATCCTAGC
R: CCGCACTTCAGATTTCGCA
Caspase-8 F: TCTGGAGCATCTGCTGTCTG
R: CCTGCCTGGTGTCTGAAGTT
Caspase-10 F: TAGGATTGGTCCCCAACAAGA
R: GAGAAACCCTTTGTCGGGTGG
MMP2 F: TCTCCTGACATTGACCTTGGC
R: CAAGGTGCTGGCTGAGTAGATC
MMP9 F: CCTTGTGCTCTTCCCTGGAG
R: GGCCCCAGAGATTTCGACTC
TIMP1 F: ACCATGGCCCCCTTTGAGCCCCTG
R: TCAGGCTATCTGGGACCGCAGGGA
TIMP2 F: CTCGGCAGTGTGTGGGGTC
R: CGAGAAACTCCTGCTTGGGG
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time PCR analysis showed that caspase-9, Akt, and MMP2
expression was reduced in dose group cells, compared with
the control group cells. p53, caspase-3, caspase-8, caspase-
10, BID, DR4, DR5, FADD, TRADD, PARP, PTEN, PUMA,
NOXA, APAF, TIMP1, and TIMP2 expression was increased
in dose group cells, compared with the control group cells
(Fig. 2a, b; p<0.05). Akt, BCL-XL, BCl-2, and MMP-9 mes-
senger RNA (mRNA) expressions were found statistically
insignificant (p>0.05).
Migration and invasion assay
By Matrigel invasion chamber assay, the cell invasion was
significantly inhibited in the dose-treated group, compared
with the control group. Invasive cells were shown in Fig. 3a.
Data of invasion % of the two groups were shown as follow:
control group (58±8.04) % and dose group (37±5.2) %
(Fig. 3b).
Colony formation assay
Colony formation analysis was performed by using colony
formation assay. It is observed that the colony formation de-
creased in the 5 μM exendin-4-treated group, compared with
the control group (Fig. 4a). Data of colony numbers of the two
groups were shown as follows: control group (525.3±12.34)
% and exendin-4 group (380.3±11.15) % (Fig. 4b).
Wound-healing assay
Effects of exendin-4 on cell migration were detected by
wound-healing assay. According to results, exendin-4 reduced
cell migration in MCF-7 cells, compared with the control
group. Images at 0, 16, and 24 h were given in Fig. 5.
Discussion
We report in this article that exendin-4 significantly inhibits
the proliferation of MCF-7 breast cancer cells and induces
apoptosis via the modulation of apoptosis-related genes which
play a role in extrinsic pathway and cell survival genes. Fur-
thermore, effects of exendin-4 on cell migration, cell invasion,
and colony formation capacity were evaluated in this study. It
was shown that it inhibits migration, cell invasion, and colony
formation capacity of breast cancer cells.
Recent advances about incretin-based therapy including
GLP-1R agonists and dipeptidyl peptidase-4 inhibition have
enabled popularity in diabetes treatment throughout the world
[18]. Incretin therapy has many advantages such as pancreatic
β cell protection, lower risk of weight increase, and less hy-
poglycemic attacks [19]. Incretin therapy is also expected to
have effects in tissue-conservation beyond its glucose-
lowering capability [20, 21]. Recent studies demonstrated that
exendin-4 has pleiotropic effects that extend beyond its
hypoglycaemic activity and anticarcinogenic potential effects
[9, 16, 17, 21].
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Fig. 1 Effect of exendin-4 on the viability ofMCF-7 cells. The cells were
treated with exendin-4 and at different concentrations and time intervals,
and their proliferation was assessed by XTT assay. Data are the average
results of three independent experiments. Asterisk IC50 dose of exendin-4
in MCF-7 breast cancer cells was detected 5 μM/ml at 48th hour
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Fig. 2 a The mRNA expressions of genes relative to GAPDH mRNA
expression were studied on real-time RT-PCR. The expression of these
genes reduced in the exendin-4-treated cells, compared with the control
cells. b Invasion related to mRNA gene expression change was
demonstrated in the graph. These given mRNA fold changes were
found statistically significant (p<0.05). mRNA changes of genes which
were found statistically insignificant (p>0.05) were not shown
2650 Tumor Biol. (2016) 37:2647–2653
In a previous study, it is showed that exendin-4 has anti-
carcinogenic effects in CT26 murine colon cancer cells by
increasing increase intracellular cAMP levels and inhibiting
glycogen synthase kinase 3 and ERK-MAPK activation, de-
creasing colony formation, and modulating apoptosis [17].
Luciani et al. defined the effects of exendin-4 on cell adhesion,
differentiation, and migration of neuroblastoma cells. They
demonstrated that GLP1-R stimulation inhibited migration
of cells independently of the chemotactic stimulus used and
also exendin-4 inhibited cell migration via IGF-1 and PDGF
induction [16]. It has recently showed that exendin-4 has an-
titumor potential effects associated with production of cAMP
in breast cancer [9]. Unlike previous studies, we focused on
evaluating of exendin-4 and its molecular effect mechanisms
related to apoptosis in MCF-7 cells. Invasion and migration
are key process of tumor progression and closely related to
breast cancer recurrence. Therefore, exendin-4 and its effects
with underlying molecular mechanisms on invasion and mi-
gration were studied. Genes which play a role in extrinsic and
intrinsic pathway of apoptosis were analyzed by RT-PCR and
according to results, exendin-4 induced expressions of extrin-
sic pathway genes. Furthermore, exendin-4 reduced cell inva-
sion by downregulatingMMP2 and upregulating TIMP1 and
TIMP2 mRNA expressions.
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Fig. 3 a Migration and invasion
assay of MCF-7 cells. Cells that
passed through the membrane
were counted in ten representative
areas. b Summary graph for
invasion were also shown
respectively. Data was presented
as mean±SD. n=3, *p<0.05
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Fig. 4 a Exendin-4 decreases MCF-7 cell colony formation. Colonies
were stained with crystal violet. b The number of colonies was
significantly decreased in cells treated with exendin-4 compared with
the control cells. Data are expressed as mean±SD, n=3, *p<0.05
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In many studies done through breast cancer patients, the
results showed that obesity and T2DM have been related to
breast cancer risk and poor prognosis [4–9]. DM and cancer
share many common mechanisms, containing increased insu-
lin and insulin-like growth factor (IGF) signaling, dysregula-
tion of ovarian steroid hormones, and chronic inflammation
[22–24]. Besides, other factors may be associated with T2DM
being correlated with decreased postprandial secretion and
GLP-1 activity [25–28]. Decreased GLP-1 levels which exist
in diabetes may play a role between diabetes and increased
risk of breast cancer [9].
Because of T2DM incidence increase day by day around
the world, exposure to GLP-1R agonists may affect a lot of
women. Studies about the effects of GLP-1R agonists on ma-
lignant diseases have been limited. Ligumsky et al. suggested
in their study that there are not any association between GLP-
1 agonists and the risk of breast cancer; conversely, GLP-1
agonists lead to proliferation, migration, cell invasion, and
colony formation inhibition [9]. Due to complex molecular
signaling pathways such as cell growth, survival, and invasion
in breast cancer, the effects of GLP-1 on these pathways
should be studied more in detail.
In conclusion, molecules that have been studied as poten-
tial anticancer agent for the improvement of treatment options
are one of the most important research issues. For the deter-
mination of these novel agents, the molecular mechanisms
related to apoptosis and cell survival of breast cancer cells
need more studies. According to our results about the effects
of exendin-4, this agent significantly inhibits the proliferation
of MCF-7 breast cancer cells and induces apoptosis via the
modulation of apoptosis-related genes which play a role in
extrinsic pathway and cell survival genes. Furthermore, ef-
fects of exendin-4 on cell migration, cell invasion, and colony
formation capacity were evaluated in this study. As a result,
exendin-4 may be a novel potential agent and may play a role
in the investigation of therapeutic strategies for breast cancer.
Therefore, more studies should be designed to find optimal
safety dose of exendin-4 and to elucidate to underlying mo-
lecular effect mechanism.
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